Related Experiment Video

Updated: May 12, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Heart transplantation and left ventricular assist device therapy: two comparable options in end-stage heart failure?

Jens Garbade1, Markus J Barten, Hartmuth B Bittner

  • 1Department of Cardiac Surgery, Heart Center, University of Leipzig, Leipzig, Germany. garbade@med.uni-leipzig.de

Clinical Cardiology
|April 19, 2013
PubMed

Insights

Left ventricular assist device (LVAD) therapy offers a promising alternative for advanced heart failure patients awaiting heart transplantation. This review compares LVADs to transplantation and discusses future LVAD advancements.

Area of Science:

  • Cardiology
  • Medical Devices
  • Surgical Innovation

Background:

  • Heart transplantation is the primary curative treatment for chronic heart failure, with a 10-year survival rate of approximately 50%.
  • A significant shortage of donor organs and an increasing number of patients awaiting heart transplantation necessitate the exploration of alternative therapies.
  • Left ventricular assist devices (LVADs) are emerging as a crucial alternative strategy for managing advanced heart failure.

Purpose of the Study:

  • To evaluate the clinical utility and long-term outcomes of a specific miniaturized LVAD compared to heart transplantation.
  • To explore future advancements and optimization of LVAD technology.
  • To discuss the challenges associated with using LVADs as an alternative to heart transplantation within a 5-year perspective.

Main Methods:

  • Review of clinical data and long-term outcomes of a miniaturized continuous-flow LVAD.
  • Analysis of current trends and technical advancements in LVAD development.
  • Discussion of challenges and future outlook for LVADs as alternatives to heart transplantation.

Main Results:

  • Miniaturized LVADs demonstrate evolving potential as a bridge to transplantation or destination therapy for advanced heart failure.
  • Continuous-flow pump technology is advancing, improving the viability of LVADs in clinical practice.
  • The comparative efficacy and role of LVADs versus heart transplantation remain subjects of ongoing clinical discussion and research.

Conclusions:

  • LVAD therapy represents a significant development in managing advanced heart failure, offering an alternative to traditional heart transplantation.
  • Ongoing technical improvements in LVADs are crucial for enhancing patient outcomes and expanding their application.
  • Careful consideration of challenges and future advancements is necessary to fully integrate LVADs as a viable alternative to heart transplantation.

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Implantation of the Syncardia Total Artificial Heart16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...